I would say that shareholder produced lists should be lightly referenced and not etched in stone. I have played in the drug development arena. Things change, get shifted around slightly, but in the end the overall strategy remains the same. Creating a list with omitted items and things that have potentially changed timelines slightly is not really helpful. Creating a list and then saying the CEO missed the 'deadline' is ridiculous. If you or JP don't like it, get out. Seriously. It's that easy. That's how investing works. I honestly can't believe that people who are so unhappy with their investment stay in the investment. If I was unhappy and questioning it then I would sell. That tells me games are being played by the people that do it. JP's constant 'reminders' each day are childish.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links